Stock Screener App

無料 -

インストール

1.19

0.84% 0.0099

after-market

アフターアワーズ： 1.19

Barinthus Biotherapeutics Plc Adr (BRNS)

概要ニュース株価時系列 Financials ディスカッション予測

Barinthus Biotherapeutics Plc Adr (BRNS) 最新ニュース

Barinthus Bio launches Phase 1 celiac disease therapy trial - Investing.com

Barinthus Biotherapeutics appoints new COO - Investing.com

BRNS Stock Touches 52-Week Low at $1.14 Amid Market Challenges - Investing.com UK

Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket ... - Benzinga

Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket By ... - Investing.com UK

Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga

Barinthus Bio refocuses on hepatitis B and celiac disease treatments By Investing.com - Investing.com

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections - GlobeNewswire Inc.

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B - GlobeNewswire Inc.

Market Update: Barinthus Biotherapeutics Plc. ADR (BRNS) Sees Negative Movement, Closing at 2.00 – DWinneX - The Dwinnex

Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024 - Investing.com India

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments - Investing.com India

Kintara Therapeutics restructures share designations By Investing.com - Investing.com

Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives - Benzinga

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections - GlobeNewswire Inc.

Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates - Zacks Investment Research

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates - Yahoo Finance

ANVS Stock Quote Price and Forecast - CNN

TPST Stock Quote Price and Forecast - CNN

Vaccitech (VACC) Stock Price, News & Analysis - MarketBeat

ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN

$358.35

0.05%

$21.90

4.86%

$224.51

2.79%

$66.83

1.64%

$118.77

0.47%

$542.08

1.11%

Yahooで開く | Google で開く | Finviz で開く | Open in MarketWatch | Open in EDGAR | Open in Reuters